Literatur
-
1
Capelastegui A, Espana P P, Quintana J M. et al .
Improvement of process-of-care and outcomes after implementing a guideline for the management of community-acquired pneumonia: a controlled before-and-after design study.
Clin Infect Dis.
2004;
39 (7)
955-963
-
2
Dean N C, Silver M P, Bateman K A. et al .
Decreased mortality after implementation of a treatment guideline for community-acquired pneumonia.
Am J Med.
2001;
110 (6)
451-457
-
3
Gleason P P, Kapoor W N, Stone R A. et al .
Medical outcomes and antimicrobial costs with the use of the American Thoracic Society guidelines for outpatients with community-acquired pneumonia.
JAMA.
1997;
278 (1)
32-39
-
4
Al Eidan F A, McElnay J C, Scott M G. et al .
Use of a treatment protocol in the management of community-acquired lower respiratory tract infection.
J Antimicrob Chemother.
2000;
45 (3)
387-394
-
5
Brown R B, Iannini P, Gross P. et al .
Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia: analysis of a hospital claims-made database.
Chest.
2003;
123 (5)
1503-1511
-
6
Lorenz W, Ollenschläger G.
Das Leitlinien-Manual.
Z Arztl Fortbild Qualitätssich.
2001;
95 (Suppl 1)
1-84
-
7
American Thoracic Society .
Hospital-acquired pneumonia in adults: Diagnosis, assessment, initial therapy, and prevention: A consensus statement.
Am J Respir Crit Care Med.
1996;
153
1711-1725
-
8
Tablan O C, Anderson L J, Besser R. et al .
Guidelines for preventing health-care - associated pneumonia, 2003: recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee.
MMWR Recomm Rep.
2004;
53 (RR-3)
1-36
-
9
Toubes E, Singh K, Yin D. et al .
Risk factors for antibiotic-resistant infection and treatment outcomes among hospitalized patients transferred from long-term care facilities: does antimicrobial choice make a difference?.
Clin Infect Dis.
2003;
36 (6)
724-730
-
10
Worth G, Buhl R, Cegla U. et al .
Leitlinie der Deutschen Atemwegsliga und der Deutschen Gesellschaft für Pneumologie zur Diagnostik und Therapie von Patienten mit chronisch obstruktiver Bronchitis und Lungenemphysem (COPD).
Pneumologie.
2003;
56 (11)
704-738
-
11
Dalhoff K, Ewig S, Höffken G. et al .
Empfehlungen zur Diagnostik, Therapie und Prävention von Pneumonien bei erworbenem Immundefizit.
Pneumologie.
2003;
56 (12)
807-831
-
12
Lopez A D, Murray C C.
The global burden of disease, 1990 - 2020.
Nat Med.
1998;
4 (11)
1241-1243
-
13 Statistisches Bundesamt .Diagnosedaten der Krankenhauspatientinnen und -patienten 2002. 6.2 ed 2004
-
14
Marrie T J, Lau C Y, Wheeler S L. et al .
A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin.
JAMA.
2000;
283 (6)
749-755
-
15
Center for Disease Control and Prevention .
Introduction to Table V. Premature deaths, monthly mortality, and monthly physician contacts - United States.
MMWR Morb Mortal Wkly Rep.
1997;
46
556-561
-
16
Marston B J, Plouffe J F, File Jr T M. et al .
Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance Study in Ohio. The Community-Based Pneumonia Incidence Study Group.
Arch Intern Med.
1997;
157 (15)
1709-1718
-
17
Fine M J, Smith M A, Carson C A. et al .
Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis.
JAMA.
1996;
275 (2)
134-141
-
18 Statistisches Bundesamt .Todesursachen in Deutschland. 4 ed 2004
-
19 Welte T, Marre R, Suttorp N. Das Kompetenznetzwerk Ambulant erworbene Pneumonie (CAPNETZ). Ein erster Zwischenbericht. Internist (Berl) 2004
-
20
Nowak D, Dietrich E S, Oberender P. et al .
Krankheitskosten von COPD in Deutschland.
Pneumologie.
2004;
58
837-844
-
21
Fang G D, Fine M, Orloff J. et al .
New and emerging etiologies for community-acquired pneumonia with implications for therapy. A prospective multicenter study of 359 cases.
Medicine.
1990;
69
307-316
-
22
Lim W S, Macfarlane J T, Boswell T C. et al .
Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines.
Thorax.
2001;
56 (4)
296-301
-
23
Ruiz M, Ewig S, Marcos M A. et al .
Etiology of community-acquired pneumonia in hospitalized patients: Impact of age, comorbidity and severity.
Am J Respir Crit Care Med.
1999;
160
397-405
-
24
El Solh A A, Sikka P, Ramadan F. et al .
Etiology of severe pneumonia in the very elderly.
Am J Respir Crit Care Med.
2001;
163 (3 Pt 1)
645-651
-
25
Arancibia F, Bauer T T, Torres A. et al .
Community-acquired Pneumonia caused by Gram-negative bacteria: Incidence and risk and prognosis.
Eur Respir J.
1999;
14 (Suppl. 30)
419s
-
26
Bartlett J G, Mundy L M.
Community-Acquired Pneumonia.
The New England Journal of Medicine.
1995;
333 (24)
1618-1624
-
27
Jokinen C, Heiskanen L, Juvonen H. et al .
Microbial etiology of community-acquired pneumonia in the adult population of 4 municipalities in eastern Finland.
Clin Infect Dis.
2001;
32 (8)
1141-1154
-
28
Finch R G, Woodhead M A.
Practical considerations and guidelines for the management of community-acquired pneumonia.
Drugs.
1998;
55
31-45
-
29
Macfarlane J T, Colville A, Guion A. et al .
Prospective study of aetiology and outcome of adults lower-respiratory-tract infection in the community.
Lancet.
1993;
341
511-514
-
30
Macfarlane J T, Holmes W, Gard P. et al .
Prospective study of the incidence, aetiology and outcome of adult lower respiratory tract illness in the community.
Thorax.
2001;
56
109-114
-
31
Höffken G, Steinhoff D, Lode H. et al .
Ätiologie von ambulant erworbenen Pneumonien bei älteren Menschen.
Chemotherapie J.
1995;
4
13-19
-
32
Lim W S, Macfarlane J T.
A prospective comparison of nursing home acquired pneumonia with community acquired pneumonia.
Eur Respir J.
2001;
18 (2)
362-368
-
33
Ewig S, Torres A, Marcos M A. et al .
Factors associated with unknown aetiology in patients with community-acquired pneumonia.
Eur Respir J.
2002;
20 (5)
1254-1262
-
34
Allewelt M, Steinhoff D, Rahlwes M. et al .
Wandel im Erregerspektrum ambulant-erworbener Pneumonien (1982 - 1992).
Dtsch Med Wochenschr.
1997;
122 (34 - 35)
1027-1032
-
35
Riquelme R, Torres A, El-Ebiary M. et al .
Community-acquired pneumonia in the elderly. Clinical and nutritional aspects.
Am J Respir Crit Care Med.
1997;
156 (6)
1908-1914
-
36
Leroy O, Santre C, Beuscart C. et al .
A five-year study of severe community-acquired pneumonia with emphasis on prognosis in patients admitted to an intensive care unit.
Intensive Care Med.
1995;
21 (1)
24-31
-
37
Rello J, Bodi M, Mariscal D. et al .
Microbiological Testing and Outcome of Patients With Severe Community-Acquired Pneumonia.
Chest.
2003;
123 (1)
174-180
-
38
Rello J, Catalan M, Diaz E. et al .
Associations between empirical antimicrobial therapy at the hospital and mortality in patients with severe community-acquired pneumonia.
Intensive Care Med.
2002;
28 (8)
1030-1035
-
39
Clavo-Sanchez A J, Giron-Gonzalez J A, Lopez-Prieto D. et al .
Multivariate analysis of risk factors for infection due to penicllin-resistant and multidrug-resistant Streptococcus pneumoniae: A multicenter study.
Clin Infect Dis.
1997;
24
1052-1059
-
40
Lück P C, Lobeck G, Stenzel G. et al .
[Legionella pneumonia after travel to Mediterranean countries].
Z Arztl Fortbild (Jena).
1994;
88 (5 - 6)
433-436
-
41
Garcia-Ordonez M A, Garcia-Jimenez J M, Paez F. et al .
Clinical aspects and prognostic factors in elderly patients hospitalised for community-acquired pneumonia.
Eur J Clin Microbiol Infect Dis.
2001;
20 (1)
14-19
-
42
Woodhead M.
Pneumonia in the elderly.
J Antimicrob Chemother.
1994;
34 Suppl A
85-92
-
43
Riquelme R, Torres A, El-Ebiary M. et al .
Community-acquired pneumonia in the elderly: a multivariate analysis of risk and prognostic factors.
Am J Respir Crit Care Med.
1996;
154 (5)
1450-1455
-
44
Sopena N, Sabria M, Pedro-Botet M L. et al .
Prospective study of community-acquired pneumonia of bacterial etiology in adults.
Eur J Clin Microbiol Infect Dis.
1999;
18 (12)
852-858
-
45
Arancibia F, Ewig S, Martinez J A. et al .
Antimicrobial treatment failures in patients with community-acquired pneumonia: Causes and prognostic implications.
Am J Respir Crit Care Med.
2000;
162
154-160
-
46
Bartlett J G, Dowell S F, Mandell L A. et al .
Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America.
Clin Infect Dis.
2000;
31 (2)
422-425
-
47
Niederman M S, Mandell L A, Anzueto A. et al .
Guidelines for the Management of Adults with Community-acquired Pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention.
Am J Respir Crit Care Med.
2001;
163 (7)
1730-1754
-
48
Arancibia F, Bauer T T, Ewig S. et al .
Community-acquired Pneumonia caused by Gram-negative bacteria: Incidence and risk and prognosis.
Arch Intern Med.
2002;
162 (16)
1849-1858
-
49
Dahmash N S, Chowdhury M N.
Re-evaluation of pneumonia requiring admission to an intensive care unit: a prospective study.
Thorax.
1994;
49 (1)
71-76
-
50
Ruiz M, Ewig S, Torres A. et al .
Severe community-acquired pneumonia. Risk factors and follow-up epidemiology.
Am J Respir Crit Care Med.
1999;
160
923-929
-
51
Torres A, Serra B J, Ferrer A. et al .
Severe community-acquired pneumonia. Epidemiology and prognostic factors.
Am Rev Respir Dis.
1991;
144 (2)
312-318
-
52
Roux A de, Marcos M A, Garcia E. et al .
Viral Community-Acquired Pneumonia in Nonimmunocompromised Adults.
Chest.
2004;
125 (4)
1343-1351
-
53
Robertson L, Caley J P, Moore J.
Importance of Staphylococcus aureus in pneumonia in the 1957 epidemic of influenza A.
Lancet.
1958;
2 (7040)
233-236
-
54
Deeks S L, Palacio R, Ruvinsky R. et al .
Risk factors and course of illness among children with invasive penicillin-resistant Streptococcus pneumoniae.The Streptococcus pneumoniae Working Group.
Pediatrics.
1999;
103 (2)
409-413
-
55
Henriques B, Kalin M, Ortqvist A. et al .
Molecular epidemiology of Streptococcus pneumoniae causing invasive disease in 5 countries.
J Infect Dis.
2000;
182 (3)
833-839
-
56
Moroney J F, Fiore A E, Harrison L H. et al .
Clinical outcomes of bacteremic pneumococcal pneumonia in the era of antibiotic resistance.
Clin Infect Dis.
2001;
33 (6)
797-805
-
57
Pallares R, Linares J, Vadillo M. et al .
Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain.
N Engl J Med.
1995;
333
474-480
-
58
Yu V L, Chiou C C, Feldman C. et al .
An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome.
Clin Infect Dis.
2003;
37 (2)
230-237
-
59
Feikin D RJ, Schuchat A, Kolczak M. et al .
Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995 - 1997.
Am J Public Health.
2000;
90 (2)
223-229
-
60
Reinert R R, Al-Lahham A, Lemperle M. et al .
Emergence of macrolide and penicillin resistance among invasive pneumococcal isolates in Germany.
J Antimicrob Chemother.
2002;
49 (1)
61-68
-
61
Reinert R R, Al Lahham A, Lutticken R. et al .
Characterization of clinical Streptococcus pneumoniae strains from Germany with decreased susceptibility to fluoroquinolones.
J Antimicrob Chemother.
2002;
49 (6)
1015-1018
-
62
Jacobs M R, Felmingham D, Appelbaum P C. et al .
The Alexander Project 1998 - 2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents.
J Antimicrob Chemother.
2003;
52 (2)
229-246
-
63
Sahm D F, Jones M E, Hickey M L. et al .
Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in Asia and Europe, 1997 - 1998.
J Antimicrob Chemother.
2000;
45 (4)
457-466
-
64
Reinert R R, Rodloff A C, Halle E. et al .
Antibacterial resistance of community-acquired respiratory tract pathogens recovered from patients in Germany and activity of the Ketolide Telithromycin: results from the PROTEKT surveillance study (1999 - 2000).
Chemotherapy.
2004;
50 (3)
143-151
-
65 Kresken M, Hafner D, Schmitz F J. et al .Resistenzsituation bei klinisch wichtigen Infektionserregern gegenüber Antibiotika in Deutschland und im mitteleuropäischen Raum. Bericht über die Ergebnisse einer multizentrischen Studie der Arbeitsgemeinschaft Empfindlichkeitsprüfungen & Resistenz der Paul-Ehrlich-Gesellschaft für Chemotherapie aus dem Jahre 2001. Bonn: Antiinfectives Intelligence 2003
-
66
Fogarty C, Goldschmidt R, Bush K.
Bacteremic pneumonia due to multidrug-resistant pneumococci in 3 patients treated unsuccessfully with azithromycin and successfully with levofloxacin.
Clin Infect Dis.
2000;
31 (2)
613-615
-
67
Kelley M A, Weber D J, Gilligan P. et al .
Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin.
Clin Infect Dis.
2000;
31 (4)
1008-1011
-
68
Waterer G W, Wunderink R G, Jones C B.
Fatal pneumococcal pneumonia attributed to macrolide resistance and azithromycin monotherapy.
Chest.
2000;
118 (6)
1839-1840
-
69
Kays M B, Wack M F, Smith D W. et al .
Azithromycin treatment failure in community-acquired pneumonia caused by Streptococcus pneumoniae resistant to macrolides by a 23S rRNA mutation.
Diagn Microbiol Infect Dis.
2002;
43 (2)
163-165
-
70
Musher D M, Dowell M E, Shortridge V D. et al .
Emergence of macrolide resistance during treatment of pneumococcal pneumonia.
N Engl J Med.
2002;
346 (8)
630-631
-
71
Lonks J R, Garau J, Gomez L. et al .
Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae.
Clin Infect Dis.
2002;
35 (5)
556-564
-
72
Kerkhoven D van, Peetermans W E, Verbist L. et al .
Breakthrough pneumococcal bacteraemia in patients treated with clarithromycin or oral beta-lactams.
J Antimicrob Chemother.
2003;
51 (3)
691-696
-
73
Descheemaeker P, Chapelle S, Lammens C. et al .
Macrolide resistance and erythromycin resistance determinants among Belgian Streptococcus pyogenes and Streptococcus pneumoniae isolates.
J Antimicrob Chemother.
2000;
45 (2)
167-173
-
74
Johnson D M, Sader H S, Fritsche T R. et al .
Susceptibility trends of haemophilus influenzae and Moraxella catarrhalis against orally administered antimicrobial agents: five-year report from the SENTRY Antimicrobial Surveillance Program.
Diagn Microbiol Infect Dis.
2003;
47 (1)
373-376
-
75
Davidson R, Cavalcanti R, Brunton J L. et al .
Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia.
N Engl J Med.
2002;
346 (10)
747-750
-
76
Ross J J, Worthington M G, Gorbach S L.
Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia.
N Engl J Med.
2002;
347 (1)
65-67
-
77
Anderson K B, Tan J S, File Jr T M. et al .
Emergence of levofloxacin-resistant pneumococci in immunocompromised adults after therapy for community-acquired pneumonia.
Clin Infect Dis.
2003;
37 (3)
376-381
-
78
Felmingham D, Reinert R R, Hirakata Y. et al .
Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and compatative in vitro activity of the ketolide, telithromycin.
J Antimicrob Chemother.
2002;
50 Suppl S1
25-37
-
79
Canton R, Morosini M, Enright M C. et al .
Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant Streptococcus pneumoniae: data from the global PROTEKT surveillance programme.
J Antimicrob Chemother.
2003;
52 (6)
944-952
-
80
Johnson A P, Sheppard C L, Harnett S J. et al .
Emergence of a fluoroquinolone-resistant strain of Streptococcus pneumoniae in England.
J Antimicrob Chemother.
2003;
52 (6)
953-960
-
81 Mauch H, Wagner J, Marklein G. et al .MIQ 7 Qualitätsstandards in der mikrobiologisch-infektiologischen Diagnostik - Infektionen der tiefen Atemwege. Teil 1 ed. Urban und Schwarzenberg 1999
-
82
Murray P R, Washington J A.
Microscopic and baceriologic analysis of expectorated sputum.
Mayo Clin Proc.
1975;
50 (6)
339-344
-
83
Geckler R W, Gremillion D H, McAllister C K. et al .
Microscopic and bacteriological comparison of paired sputa and transtracheal aspirates.
J Clin Microbiol.
1977;
6 (4)
396-399
-
84
Roson B, Carratala J, Verdaguer R. et al .
Prospective study of the usefulness of sputum Gram stain in the initial approach to community-acquired pneumonia requiring hospitalization.
Clin Infect Dis.
2000;
31 (4)
869-874
-
85
Mandell L A, Marrie T J, Grossman R F. et al .
Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group.
Clin Infect Dis.
2000;
31 (2)
385-421
-
86
Theerthakarai R, El Halees W, Ismail M. et al .
Nonvalue of the Initial Microbiological Studies in the Management of Nonsevere Community-Acquired Pneumonia.
Chest.
2001;
119 (1)
181-184
-
87
Chalasani N P, Valdecanas M A, Gopal A K. et al .
Clinical utility of blood cultures in adult patients with community-acquired pneumonia without defined underlying risks.
Chest.
1995;
108 (4)
932-936
-
88
Waterer G W, Wunderink R G.
The influence of the severity of community-acquired pneumonia on the usefulness of blood cultures.
Respir Med.
2001;
95 (1)
78-82
-
89
Lentino J R, Lucks D A.
Nonvalue of sputum culture in the management of lower respiratory tract infections.
J Clin Microbiol.
1987;
25 (5)
758-762
-
90
Dominguez J A, Matas L, Manterola J M. et al .
Comparison of radioimmunoassay and enzyme immunoassay kits for detection of Legionella pneumophila serogroup 1 antigen in both concentrated and nonconcentrated urine samples.
J Clin Microbiol.
1997;
35 (6)
1627-1629
-
91
Gutierrez F, Masia M, Rodriguez J C. et al .
Evaluation of the Immunochromatographic Binax NOW Assay for Detection of Streptococcus pneumoniae Urinary Antigen in a Prospective Study of Community-Acquired Pneumonia in Spain.
Clin Infect Dis.
2003;
36 (3)
286-292
-
92
Dominguez J, Gali N, Blanco S. et al .
Detection of Streptococcus pneumoniae Antigen by a Rapid Immunochromatographic Assay in Urine Samples.
Chest.
2001;
119 (1)
243-249
-
93
Smith M D, Derrington P, Evans R. et al .
Rapid diagnosis of bacteremic pneumococcal infections in adults by using the Binax NOW Streptococcus pneumoniae urinary antigen test: a prospective, controlled clinical evaluation.
J Clin Microbiol.
2003;
41 (7)
2810-2813
-
94
Marcos M A, Jimenez de Anta M T, de la Bellacasa J P. et al .
Rapid urinary antigen test for diagnosis of pneumococcal community-acquired pneumonia in adults.
Eur Respir J.
2003;
21 (2)
209-214
-
95
Ishida T, Hashimoto T, Arita M. et al .
A 3-Year prospective study of a urinary antigen-detection for Streptoccus pneumoniae in community acquired pneumonia: utility and clinical impact on the reported etiology.
J Infect Chemother.
2004;
10
359-363
-
96
Murdoch D R, Laing R T, Mills G D. et al .
Evaluation of a rapid immunochromatographic test for detection of Streptococcus pneumoniae antigen in urine samples from adults with community-acquired pneumonia.
J Clin Microbiol.
2001;
39 (10)
3495-3498
-
97
Murdoch D R, Laing R T, Cook J M.
The NOW S. pneumoniae urinary antigen test positivity rate 6 weeks after pneumonia onset and among patients with COPD.
Clin Infect Dis.
2003;
37 (1)
153-154
-
98
Edelstein P H, Meyer R D, Finegold S M.
Laboratory diagnosis of Legionnaires' disease.
Am Rev Respir Dis.
1980;
121 (2)
317-327
-
99
Zuravleff J J, Yu V L, Shonnard J W. et al .
Diagnosis of Legionnaires' disease. An update of laboratory methods with new emphasis on isolation by culture.
JAMA.
1983;
250 (15)
1981-1985
-
100
Murdoch D R.
Nucleic acid amplification tests for the diagnosis of pneumonia.
Clin Infect Dis.
2003;
36 (9)
1162-1170
-
101
Helbig J H, Uldum S A, Bernander S. et al .
Clinical utility of urinary antigen detection for diagnosis of community-acquired, travel-associated, and nosocomial legionnaires' disease.
J Clin Microbiol.
2003;
41 (2)
838-840
-
102
Dowell S F, Garman R L, Liu G. et al .
Evaluation of Binax NOW, an assay for the detection of pneumococcal antigen in urine samples, performed among pediatric patients.
Clin Infect Dis.
2001;
32 (5)
824-825
-
103
Kashuba A D, Ballow C H.
Legionella urinary antigen testing: potential impact on diagnosis and antibiotic therapy.
Diagn Microbiol Infect Dis.
1996;
24 (3)
129-139
-
104
Wever P C, Yzerman E P, Kuijper E J. et al .
Rapid diagnosis of Legionnaires' disease using an immunochromatographic assay for Legionella pneumophila serogroup 1 antigen in urine during an outbreak in the Netherlands.
J Clin Microbiol.
2000;
38 (7)
2738-2739
-
105
Helbig J H, Uldum S A, Luck P C. et al .
Detection of Legionella pneumophila antigen in urine samples by the BinaxNOW immunochromatographic assay and comparison with both Binax Legionella Urinary Enzyme Immunoassay (EIA) and Biotest Legionella Urin Antigen EIA.
J Med Microbiol.
2001;
50 (6)
509-516
-
106
Guerrero C, Toldos C M, Yague G. et al .
Comparison of diagnostic sensitivities of three assays (Bartels enzyme immunoassay [EIA], Biotest EIA, and Binax NOW immunochromatographic test) for detection of Legionella pneumophila serogroup 1 antigen in urine.
J Clin Microbiol.
2004;
42 (1)
467-468
-
107
Yzerman E P, Den Boer J W, Lettinga K D. et al .
Sensitivity of three urinary antigen tests associated with clinical severity in a large outbreak of Legionnaires' disease in The Netherlands.
J Clin Microbiol.
2002;
40 (9)
3232-3236
-
108
Kessler H H, Reinthaler F F, Pschaid A. et al .
Rapid detection of Legionella species in bronchoalveolar lavage fluids with the EnviroAmp Legionella PCR amplification and detection kit.
J Clin Microbiol.
1993;
31 (12)
3325-3328
-
109
Weir S C, Fischer S H, Stock F. et al .
Detection of Legionella by PCR in respiratory specimens using a commercially available kit.
Am J Clin Pathol.
1998;
110 (3)
295-300
-
110
Cloud J L, Carroll K C, Pixton P. et al .
Detection of Legionella species in respiratory specimens using PCR with sequencing confirmation.
J Clin Microbiol.
2000;
38 (5)
1709-1712
-
111
Murdoch D R, Anderson T P, Beynon K A. et al .
Evaluation of a PCR Assay for Detection of Streptococcus pneumoniae in Respiratory and Nonrespiratory Samples from Adults with Community-Acquired Pneumonia.
J Clin Microbiol.
2003;
41 (1)
63-66
-
112
Reischl U, Linde H J, Lehn N. et al .
Direct detection and differentiation of Legionella spp. and Legionella pneumophila in clinical specimens by dual-color real-time PCR and melting curve analysis.
J Clin Microbiol.
2002;
40 (10)
3814-3817
-
113
Templeton K E, Scheltinga S A, Sillekens P. et al .
Development and clinical evaluation of an internally controlled, single-tube multiplex real-time PCR assay for detection of Legionella pneumophila and other Legionella species.
J Clin Microbiol.
2003;
41 (9)
4016-4021
-
114
Welti M, Jaton K, Altwegg M. et al .
Development of a multiplex real-time quantitative PCR assay to detect Chlamydia pneumoniae, Legionella pneumophila and Mycoplasma pneumoniae in respiratory tract secretions.
Diagn Microbiol Infect Dis.
2003;
45 (2)
85-95
-
115
Kallings I, Nordstrom K.
The pattern of immunoglobulins with special reference to IgM in Legionnaires' disease patients during a 2 year follow-up period.
Zentralbl Bakteriol Mikrobiol Hyg [A].
1983;
255 (1)
27-32
-
116
Monforte R, Estruch R, Vidal J. et al .
Delayed seroconversion in Legionnaire's disease.
Lancet.
1988;
2 (8609)
513
-
117
Plouffe J F, File Jr T M, Breiman R F. et al .
Reevaluation of the definition of Legionnaires' disease: use of the urinary antigen assay. Community Based Pneumonia Incidence Study Group.
Clin Infect Dis.
1995;
20 (5)
1286-1291
-
118
Boswell T C, Marshall L E, Kudesia G.
False-positive legionella titres in routine clinical serology testing detected by absorption with campylobacter: implications for the serological diagnosis of legionnaires' disease.
J Infect.
1996;
32 (1)
23-26
-
119
Musso D, Raoult D.
Serological cross-reactions between Coxiella burnetii and Legionella micdadei.
Clin Diagn Lab Immunol.
1997;
4 (2)
208-212
-
120
Waterer G W, Baselski V S, Wunderink R G.
Legionella and community-acquired pneumonia: a review of current diagnostic tests from a clinician's viewpoint.
Am J Med.
2001;
110 (1)
41-48
-
121
Ieven M, Goossens H.
Relevance of nucleic acid amplification techniques for diagnosis of respiratory tract infections in the clinical laboratory.
Clin Microbiol Rev.
1997;
10 (2)
242-256
-
122
Ponka A, Ponka T, Sarna S. et al .
Questionable specificity of lipid antigen in the Mycoplasma pneumoniae complement fixation test in patients with extrapulmonary manifestations.
J Infect.
1981;
3 (4)
332-338
-
123
Ruuskanen O, Nohynek H, Ziegler T. et al .
Pneumonia in childhood: etiology and response to antimicrobial therapy.
Eur J Clin Microbiol Infect Dis.
1992;
11 (3)
217-223
-
124
Taylor-Robinson D.
Infections due to species of Mycoplasma and Ureaplasma: an update.
Clin Infect Dis.
1996;
23 (4)
671-682
-
125
Watkins-Riedel T, Stanek G, Daxboeck F.
Comparison of SeroMP IgA with four other commercial assays for serodiagnosis of Mycoplasma pneumoniae pneumonia.
Diagn Microbiol Infect Dis.
2001;
40 (1 - 2)
21-25
-
126
Ieven M, Ursi D, Bever H van. et al .
Detection of Mycoplasma pneumoniae by two polymerase chain reactions and role of M. pneumoniae in acute respiratory tract infections in pediatric patients.
J Infect Dis.
1996;
173 (6)
1445-1452
-
127
Abele-Horn M, Busch U, Nitschko H. et al .
Molecular approaches to diagnosis of pulmonary diseases due to Mycoplasma pneumoniae.
J Clin Microbiol.
1998;
36 (2)
548-551
-
128
Dorigo-Zetsma J W, Zaat S A, Wertheim-van Dillen P M. et al .
Comparison of PCR, culture, and serological tests for diagnosis of Mycoplasma pneumoniae respiratory tract infection in children.
J Clin Microbiol.
1999;
37 (1)
14-17
-
129
Dorigo-Zetsma J W, Verkooyen R P, Helden H P van. et al .
Molecular detection of Mycoplasma pneumoniae in adults with community-acquired pneumonia requiring hospitalization.
J Clin Microbiol.
2001;
39 (3)
1184-1186
-
130
Loens K, Ieven M, Ursi D. et al .
Detection of Mycoplasma pneumoniae by real-time nucleic acid sequence-based amplification.
J Clin Microbiol.
2003;
41 (9)
4448-4450
-
131
Ursi D, Dirven K, Loens K. et al .
Detection of Mycoplasma pneumoniae in respiratory samples by real-time PCR using an inhibition control.
J Microbiol Methods.
2003;
55 (1)
149-153
-
132
Templeton K E, Scheltinga S A, Graffelman A W. et al .
Comparison and evaluation of real-time PCR, real-time nucleic acid sequence-based amplification, conventional PCR, and serology for diagnosis of Mycoplasma pneumoniae.
J Clin Microbiol.
2003;
41 (9)
4366-4371
-
133
Loens K, Ursi D, Goossens H. et al .
Molecular diagnosis of Mycoplasma pneumoniae respiratory tract infections.
J Clin Microbiol.
2003;
41 (11)
4915-4923
-
134
Ortiz-Ruiz G, Vetter N, Isaacs R. et al .
Ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults: combined analysis of two multicentre randomized, double-blind studies.
J Antimicrob Chemother.
2004;
53 Suppl 2
ii59-ii66
-
135
Tompkins L S, Schachter J, Boman J. et al .
Collaborative multidisciplinary workshop report: detection, culture, serology, and antimicrobial susceptibility testing of Chlamydia pneumoniae.
J Infect Dis.
2000;
181 Suppl 3
S460-S461
-
136
Mandell L A, Bartlett J G, Dowell S F. et al .
Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults.
Clin Infect Dis.
2003;
37 (11)
1405-1433
-
137
Dowell S F, Peeling R W, Boman J. et al .
Standardizing Chlamydia pneumoniae assays: recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada).
Clin Infect Dis.
2001;
33 (4)
492-503
-
138
Dowell J, Pitkethly M, Bain J. et al .
A randomised controlled trial of delayed antibiotic prescribing as a strategy for managing uncomplicated respiratory tract infection in primary care.
Br J Gen Pract.
2001;
51 (464)
200-205
-
139
Reischl U, Lehn N, Simnacher U. et al .
Rapid and standardized detection of Chlamydia pneumoniae using LightCycler real-time fluorescence PCR.
Eur J Clin Microbiol Infect Dis.
2003;
22 (1)
54-57
-
140
Bartlett J G, Breiman R F, Mandell L A. et al .
Practice Guidelines for the Management of Community-Acquired Pneumonia in Adults.
Clin Infect Dis.
1998;
26
811-838
-
141
Schrag S J, Pena C, Fernandez J. et al .
Effect of short-course, high-dose amoxicillin therapy on resistant pneumococcal carriage: a randomized trial.
JAMA.
2001;
286 (1)
49-56
-
142
Dunbar L M, Wunderink R G, Habib M P. et al .
High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm.
Clin Infect Dis.
2003;
37 (6)
752-760
-
143
Diehr P, Wood R W, Bushyhead J. et al .
Prediction of pneumonia in outpatients with acute cough - a statistical approach.
J Chronic Dis.
1984;
37 (3)
215-225
-
144
Gennis P, Gallagher J, Falvo C. et al .
Clinical criteria for the detection of pneumonia in adults: guidelines for ordering chest roentgenograms in the emergency department.
J Emerg Med.
1989;
7 (3)
263-268
-
145
Heckerling P S, Tape T G, Wigton R S. et al .
Clinical prediction rule for pulmonary infiltrates.
Ann Intern Med.
1990;
113 (9)
664-670
-
146
Melbye H, Straume B, Aasebo U. et al .
Diagnosis of pneumonia in adults in general practice. Relative importance of typical symptoms and abnormal chest signs evaluated against a radiographic reference standard.
Scand J Prim Health Care.
1992;
10 (3)
226-233
-
147
Metlay J P, Kapoor W N, Fine M J.
Does this patient have community-acquired pneumonia? Diagnosing pneumonia by history and physical examination.
JAMA.
1997;
278 (17)
1440-1445
-
148
Wipf J E, Lipsky B A, Hirschmann J V. et al .
Diagnosing pneumonia by physical examination: relevant or relic?.
Arch Intern Med.
1999;
159 (10)
1082-1087
-
149
Schilling R S, Hughes J P, Dingwall-Fordyce I.
Disagreement between observers in an epidemiological study of respiratory disease.
Br Med J.
1955;
4905
65-68
-
150
Spiteri M A, Cook D G, Clarke S W.
Reliability of eliciting physical signs in examination of the chest.
Lancet.
1988;
1 (8590)
873-875
-
151
Emerman C L, Dawson N, Speroff T. et al .
Comparison of physician judgment and decision aids for ordering chest radiographs for pneumonia in outpatients.
Ann Emerg Med.
1991;
20 (11)
1215-1219
-
152
Heckerling P S.
The need for chest roentgenograms in adults with acute respiratory illness. Clinical predictors.
Arch Intern Med.
1986;
146 (7)
1321-1324
-
153
Metlay J P, Schulz R, Li Y H. et al .
Influence of age on symptoms at presentation in patients with community-acquired pneumonia.
Arch Intern Med.
1997;
157 (13)
1453-1459
-
154
Melbye H, Dale K.
Interobserver variability in the radiographic diagnosis of adult outpatient pneumonia.
Acta Radiol.
1992;
33 (1)
79-81
-
155
Young M, Marrie T J.
Interobserver variability in the interpretation of chest roentgenograms of patients with possible pneumonia.
Arch Intern Med.
1994;
154 (23)
2729-2732
-
156
Fahey T, Stocks N, Thomas T.
Quantitative systematic review of randomised controlled trials comparing antibiotic with placebo for acute cough in adults.
BMJ.
1998;
316 (7135)
906-910
-
157
Gonzales R, Steiner J F, Sande M A.
Antibiotic prescribing for adults with colds, upper respiratory tract infections, and bronchitis by ambulatory care physicians.
JAMA.
1997;
278 (11)
901-904
-
158
Gonzales R, Steiner J F, Lum A. et al .
Decreasing antibiotic use in ambulatory practice: impact of a multidimensional intervention on the treatment of uncomplicated acute bronchitis in adults.
JAMA.
1999;
281 (16)
1512-1519
-
159
Macfarlane J, Holmes W, Gard P. et al .
Reducing antibiotic use for acute bronchitis in primary care: blinded, randomised controlled trial of patient information leaflet.
BMJ.
2002;
324 (7329)
91-94
-
160
Hayden F G, Osterhaus A D, Treanor J J. et al .
Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group.
N Engl J Med.
1997;
337 (13)
874-880
-
161
Monto A S, Fleming D M, Henry D. et al .
Efficacy and safety of the neuraminidase inhibitor zanamivirin the treatment of influenza A and B virus infections.
J Infect Dis.
1999;
180 (2)
254-261
-
162
Treanor J J, Hayden F G, Vrooman P S. et al .
Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group.
JAMA.
2000;
283 (8)
1016-1024
-
163
Nicholson K G, Aoki F Y, Osterhaus A D. et al .
Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group.
Lancet.
2000;
355 (9218)
1845-1850
-
164
Monto A S, Webster A, Keene O.
Randomized, placebo-controlled studies of inhaled zanamivir in the treatment of influenza A and B: pooled efficacy analysis.
J Antimicrob Chemother.
1999;
44 Suppl B
23-29
-
165
Ohmit S E, Moler F W, Monto A S. et al .
Ribavirin utilization and clinical effectiveness in children hospitalized with respiratory syncytial virus infection.
J Clin Epidemiol.
1996;
49 (9)
963-967
-
166
Seemungal T, Harper-Owen R, Bhowmik A. et al .
Respiratory Viruses, Symptoms, and Inflammatory Markers in Acute Exacerbations and Stable Chronic Obstructive Pulmonary Disease.
Am J Respir Crit Care Med.
2001;
164
1618-1623
-
167
Rohde G, Wiethege A, Borg I. et al .
Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalization - a case-control study.
Thorax.
2003;
58
37-42
-
168
Chodosh S, McCarty J, Farkas S. et al .
Randomized, double-blind study of ciprofloxacin and cefuroxime axetil for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group.
Clin Infect Dis.
1998;
27 (4)
722-729
-
169
Angrill J, Celis R, Arancibia F. et al .
Bacterial colonization in patients with bronchiectasis: prevalence and comparison of diagnostic techniques.
American Journal of Respiratory and Critical Care Medicine Ref Type Abstract.
1999;
159 (3)
A559
-
170
Blasi F, Damato S, Cosentini R. et al .
Chlamydia pneumoniae and chronic bronchitis: association with severity and bacterial clearance following treatment.
Thorax.
2002;
57 (8)
672-676
-
171
Beaty C D, Grayston J T, Wang S P. et al .
Chlamydia pneumoniae, strain TWAR, infection in patients with chronic obstructive pulmonary disease.
Am Rev Respir Dis.
1991;
144 (6)
1408-1410
-
172
Blasi F, Legnani D, Lombardo V M. et al .
Chlamydia pneumoniae infection in acute exacerbations of COPD.
Eur Respir J.
1993;
6 (1)
19-22
-
173
Buscho R O, Saxtan D, Shultz P S. et al .
Infections with viruses and Mycoplasma pneumoniae during exacerbations of chronic bronchitis.
J Infect Dis.
1978;
137 (4)
377-383
-
174
Smith C B, Golden C A, Kanner R E. et al .
Association of viral and Mycoplasma pneumoniae infections with acute respiratory illness in patients with chronic obstructive pulmonary diseases.
Am Rev Respir Dis.
1980;
121 (2)
225-232
-
175
Mogulkoc N, Karakurt S, Isalska B. et al .
Acute purulent exacerbation of chronic obstructive pulmonary disease and Chlamydia pneumoniae infection.
Am J Respir Crit Care Med.
1999;
160 (1)
349-353
-
176
Lieberman D, Lieberman D, Shmarkov O. et al .
Serological evidence of Legionella species infection in acute exacerbation of COPD.
Eur Respir J.
2002;
19 (3)
392-397
-
177
Kessler R, Faller M, Fourgaut G. et al .
Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease.
Am J Respir Crit Care Med.
1999;
159 (1)
158-164
-
178
Anon J M, Garcia D L, Zarazaga A. et al .
Mechanical ventilation of patients on long-term oxygen therapy with acute exacerbations of chronic obstructive pulmonary disease: prognosis and cost-utility analysis.
Intensive Care Med.
1999;
25 (5)
452-457
-
179
Groenewegen K H, Schols A MWJ, Wouters E FM.
Mortality and Mortality-Related Factors After Hospitalization for Acute Exacerbation of COPD.
Chest.
2003;
124 (2)
459-467
-
180
Patil S P, Krishnan J A, Lechtzin N. et al .
In-hospital mortality following acute exacerbations of chronic obstructive pulmonary disease.
Arch Intern Med.
2003;
163 (10)
1180-1186
-
181
Donaldson G C, Seemungal T A, Bhowmik A. et al .
Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease.
Thorax.
2002;
57 (10)
847-852
-
182
Wilkinson T MA, Patel I S, Wilks M. et al .
Airway Bacterial Load and FEV1 Decline in Patients with Chronic Obstructive Pulmonary Disease.
Am J Respir Crit Care Med.
2003;
167 (8)
1090
-
183
Sethi S, Evans N, Grant B J. et al .
New strains of bacteria and exacerbations of chronic obstructive pulmonary disease.
N Engl J Med.
2002;
347 (7)
465-471
-
184
Christ-Crain M, Jaccard-Stolz D, Bingisser R. et al .
Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial.
Lancet.
2004;
363 (9409)
600-607
-
185
Nicotra M B, Rivera M, Awe R J.
Antibiotic therapy of acute exacerbations of chronic bronchitis. A controlled study using tetracycline.
Ann Intern Med.
1982;
97 (1)
18-21
-
186
Nouira S, Marghli S, Belghith M. et al .
Once daily oral ofloxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: a randomised placebo-controlled trial.
Lancet.
2001;
358
2020-2025
-
187
Sachs A P, Koeter G H, Groenier K H. et al .
Changes in symptoms, peak expiratory flow, and sputum flora during treatment with antibiotics of exacerbations in patients with chronic obstructive pulmonary disease in general practice.
Thorax.
1995;
50 (7)
758-763
-
188
Anthonisen N R, Manfreda J, Warren C PW. et al .
Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease.
Ann Intern Med.
1987;
106
196-204
-
189
Jorgensen A F, Coolidge J, Pedersen P A. et al .
Amoxicillin in treatment of acute uncomplicated exacerbations of chronic bronchitis. A double-blind, placebo-controlled multicentre study in general practice.
Scand J Prim Health Care.
1992;
10 (1)
7-11
-
190
Chodosh S, Schreurs A, Siami G. et al .
Efficacy of oral ciprofloxacin vs. clarithromycin for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group.
Clin Infect Dis.
1998;
27 (4)
730-738
-
191
Adams S G, Melo J, Luther M. et al .
Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD.
Chest.
2000;
117 (5)
1345-1352
-
192
Wilson R, Schentag J J, Ball P. et al .
A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes.
Clin Ther.
2002;
24 (4)
639-652
-
193
Wilson R, Allegra L, Huchon G. et al .
Short-term and Long-term Outcomes of Moxifloxacin Compared to Standard Antibiotic Treatment in Acute Exacerbations of Chronic Bronchitis.
Chest.
2004;
125 (3)
953-964
-
194
Ball P, Harris J M, Lowson D. et al .
Acute infective exacerbations of chronic bronchitis.
QJM.
1995;
88 (1)
61-68
-
195
Eller J, Ede A, Schaberg T. et al .
Infective exacerbations of chronic bronchitis: relation betwen bacteriologic etiology and lung function.
Chest.
1998;
113
1542-1548
-
196
Miravitlles M, Espinosa C, Fernandez-Laso E. et al .
Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection in COPD.
Chest.
1999;
116 (1)
40-46
-
197
Anzueto A, Niederman M S, Tillotson G S.
Etiology, susceptibility, and treatment of acute bacterial exacerbations of complicated chronic bronchitis in the primary care setting: ciprofloxacin 750 mg b. i. d. versus clarithromycin 500 mg b. i. d. Bronchitis Study Group.
Clin Ther.
1998;
20 (5)
885-900
-
198
Fagon J Y, Chastre J, Trouillet J L. et al .
Characterization of distal bronchial microflora during acute exacerbation of chronic bronchitis. Use of the protected specimen brush technique in 54 mechanically ventilated patients.
Am Rev Respir Dis.
1990;
142 (5)
1004-1008
-
199
Soler N, Torres A, Celis R. et al .
Bronchial microbial pattern in non-severe exacerbations of chronic obstructive pulmonary disease (COPD): A bronchoscopic study.
Eur Respir J.
2000;
16 (Supp 31)
332s
-
200
Lode H, Eller J, Linnhoff A. et al .
Levofloxacin versus clarithromycin in COPD exacerbation: focus on exacerbation-free interval.
European Respiratory Journal.
2004;
24 (6)
947-953
-
201
Zhanel G G, Ennis K, Vercaigne L. et al .
A critical review of the fluoroquinolones: focus on respiratory infections.
Drugs.
2002;
62 (1)
13-59
-
202
Neuhauser M M, Weinstein R A, Rydman R. et al .
Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use.
JAMA.
2003;
289 (7)
885-888
-
203 Drobnic M E, Sune P, Montoro J B. et al .Inhaled Tobramycin in Non-Cystic Fibrosis Patients with Bronchiectasis and Chronic Bronchial Infection with Pseudomonas aeruginosa (January). The Annals of Pharmacotherapy 2004 aph
-
204
Barker A F.
Bronchiectasis.
The New England Journal of Medicine.
2002;
346 (18)
1383-1393
-
205
Zervos M J, Heyder A M, Leroy B.
Oral telithromycin 800 mg once daily for 5 days versus cefuroxime axetil 500 mg twice daily for 10 days in adults with acute exacerbations of chronic bronchitis.
J Int Med Res.
2003;
31 (3)
157-169
-
206
Masterton R G, Burley C J.
Randomized, double-blind study comparing 5- and 7-day regimens of oral levofloxacin in patients with acute exacerbation of chronic bronchitis.
Int J Antimicrob Agents.
2001;
18 (6)
503-512
-
207
Schonhofer B, Kohler D.
Prevalence of deep-vein thrombosis of the leg in patients with acute exacerbation of chronic obstructive pulmonary disease.
Respiration.
1998;
65 (3)
173-177
-
208
Lim W S, Lewis S, Macfarlane J T.
Severity prediction rules in community acquired pneumonia: a validation study.
Thorax.
2000;
55 (3)
219-223
-
209
Fine M J, Auble T E, Yealy D M. et al .
A prediction rule to identify low-risk patients with community-acquired pneumonia.
N Engl J Med.
1997;
336
243-250
-
210
British Thoracic Society and the Public Health Laboratory Service .
Community-acquired pneumonia in adults in British hospitals in 1982 - 1983: A survey of aetiology, mortality, prognostic factors and outcome.
Q J Med.
1987;
62 (239)
195-200
-
211
Neill A M, Martin I R, Weir R. et al .
Community-acquired pneumonia: aetiology and usefulness of severity criteria on admission.
Thorax.
1996;
51
1010-1016
-
212
Ewig S, Kleinfeld T, Bauer T T. et al .
Comparative validation of prognostic rules for community-acquired pneumonia in an elderly population.
Eur Respir J.
1999;
14
370-375
-
213
Farr B M, Sloman A J, Fisch M J.
Predicting death in patients hospitalized for community-acquired pneumonia.
Ann Intern Med.
1991;
115 (6)
428-436
-
214
Karalus N C, Cursons R T, Leng R A. et al .
Community acquired pneumonia: aetiology and prognostic index evaluation.
Thorax.
1991;
46
413-418
-
215 Bauer T T, Ewig S, Marre R. et al .Prospective comparision of CURB, CRB, CRB-65 scores for predicting mortality in hospitalized patients and outpatients with CAP. in press
-
216
Lim W S, Eerden M M van der, Laing R. et al .
Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study.
Thorax.
2003;
58 (5)
377
-
217
Ewig S, Roux A de, Bauer T. et al .
Validation of predictive rules and indices of severity for community acquired pneumonia.
Thorax.
2004;
59 (5)
421-427
-
218
Roson B, Carratala J, Dorca J. et al .
Etiology, reasons for hospitalization, risk classes, and outcomes of community-acquired pneumonia in patients hospitalized on the basis of conventional admission criteria.
Clin Infect Dis.
2001;
33 (2)
158-165
-
219
Ewig S, Ruiz M, Mensa J. et al .
Severe community-acquired pneumonia: Assessment of severity criteria.
Am J Respir Crit Care Med.
1998;
158
1102-1108
-
220
Angus D C, Marrie T J, Obrosky D S. et al .
Severe community-acquired pneumonia: use of intensive care services and evaluation of American and British Thoracic Society Diagnostic criteria.
Am J Respir Crit Care Med.
2002;
166 (5)
717-723
-
221
Rivers E, Nguyen B, Havstad S. et al .
Early goal-directed therapy in the treatment of severe sepsis and septic shock.
N Engl J Med.
2001;
345 (19)
1368-1377
-
222
Mansel J K, Rosenow III E C, Smith T F. et al .
Mycoplasma pneumoniae pneumonia.
Chest.
1989;
95 (3)
639-646
-
223
Tellier G, Niederman M S, Nusrat R. et al .
Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia.
J Antimicrob Chemother.
2004;
54 (2)
515-523
-
224
Hagberg L, Torres A, Rensburg D van. et al .
Efficacy and tolerability of once-daily telithromycin compared with high-dose amoxicillin for treatment of community-acquired pneumonia.
Infection.
2002;
30 (6)
378-386
-
225
Carbon C, Moola S, Velancsics I. et al .
Telithromycin 800 mg once daily for seven to ten days is an effective and well-tolerated treatment for community-acquired pneumonia.
Clin Microbiol Infect.
2003;
9 (7)
691-703
-
226
Petitpretz P, Arvis P, Marel M. et al .
Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults.
Chest.
2001;
119 (1)
185-195
-
227
Petitpretz P, Chidiac C, Soriano F. et al .
The efficacy and safety of oral pharmacokinetically enhanced amoxycillin-clavulanate 2000/125 mg, twice daily, versus oral amoxycillin-clavulanate 1000/125 mg, three times daily, for the treatment of bacterial community-acquired pneumonia in adults.
Int J Antimicrob Agents.
2002;
20 (2)
119-129
-
228
Ailani R K, Agastya G, Ailani R K. et al .
Doxycycline is a cost-effective therapy for hospitalized patients with community-acquired pneumonia.
Arch Intern Med.
1999;
159 (3)
266-270
-
229
Gordon J J, Kauffman C A.
Superinfection with Streptococcus pneumoniae during therapy with ciprofloxacin.
Am J Med.
1990;
89 (3)
383-384
-
230
Kuru T, Lyons 3 J P.
Nonresolving or slowly resolving pneumonia.
Clin Chest Med.
1999;
20 (3)
623-651
-
231
Campbell S G, Marrie T J, Anstey R. et al .
The Contribution of Blood Cultures to the Clinical Management of Adult Patients Admitted to the Hospital With Community-Acquired Pneumonia: A Prospective Observational Study.
Chest.
2003;
123 (4)
1142-1150
-
232
Lode H, Magyar P, Muir J F. et al .
Once-daily oral gatifloxacin vs three-times-daily co-amoxiclav in the treatment of patients with community-acquired pneumonia.
Clin Microbiol Infect.
2004;
10 (6)
512-520
-
233
Okimoto N, Kurihara T, Honda N. et al .
Clinical effect of ampicillin with beta-lactamase inhibitor (sulbactam/ampicillin) on community-acquired pneumonia in the elderly.
J Infect Chemother.
2003;
9 (2)
183-186
-
234
File Jr T M, Segreti J, Dunbar L. et al .
A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia.
Antimicrob Agents Chemother.
1997;
41 (9)
1965-1972
-
235
Zuck P, Rio Y, Ichou F.
Efficacy and tolerance of cefpodoxime proxetil compared with ceftriaxone in vulnerable patients with bronchopneumonia.
J Antimicrob Chemother.
1990;
26 Suppl E
71-77
-
236
Gotfried M H, Dattani D, Riffer E. et al .
A controlled, double-blind, multicenter study comparing clarithromycin extended-release tablets and levofloxacin tablets in the treatment of community-acquired pneumonia.
Clin Ther.
2002;
24 (5)
736-751
-
237
Hoeffken G, Meyer H P, Winter J. et al .
The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia.
Respir Med.
2001;
95 (7)
553-564
-
238
Scheld W M.
Maintaining fluoroquinolone class efficacy: review of influencing factors.
Emerg Infect Dis.
2003;
9 (1)
1-9
-
239
Bohte R, Furth R van, Broek P J van den.
Aetiology of community-acquired pneumonia: a prospective study among adults requiring admission to hospital.
Thorax.
1995;
50 (5)
543-547
-
240
Fine M J, Stone R A, Singer D E. et al .
Processes and outcomes of care for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team (PORT) cohort study.
Arch Intern Med.
1999;
159 (9)
970-980
-
241
Ruiz M, Ewig S, Marcos M A. et al .
Etiology of community-acquired pneumonia in hospitalized patients: Impact of age, comorbidity and severity.
American Journal of Respiratory and Critical Care Medicine.
1999;
159 (3)
A559
-
242
Mundy L M, Auwaerter P G, Oldach D. et al .
Community-acquired pneumonia. Impact of immune status.
Am J Respir Crit Care Med.
1995;
152
1309-1315
-
243
Lieberman D, Schlaeffer F, Boldur I. et al .
Multiple pathogens in adult patients admitted with community-acquired pneumonia: a one year prospective study of 346 consecutive patients.
Thorax.
1996;
51
179-184
-
244
Syrjala H, Broas M, Suramo I. et al .
High-resolution computed tomography for the diagnosis of community-acquired pneumonia.
Clin Infect Dis.
1998;
27 (2)
358-363
-
245
Ahkee S, Srinath L, Ramirez J.
Community-acquired pneumonia in the elderly: association of mortality with lack of fever and leukocytosis.
South Med J.
1997;
90 (3)
296-298
-
246
Almirall J, Bolibar I, Toran P. et al .
Contribution of C-Reactive Protein to the Diagnosis and Assessment of Severity of Community-Acquired Pneumonia.
Chest.
2004;
125 (4)
1335-1342
-
247
Smith R P, Lipworth B J, Cree I A. et al .
C-reactive protein. A clinical marker in community-acquired pneumonia.
Chest.
1995;
107
1028-1031
-
248
Meehan T P, Fine M J, Krumholz H M. et al .
Quality of care, process, and outcomes in elderly patients with pneumonia.
JAMA.
1997;
278 (23)
2080-2084
-
249
Josephson M A, Agger W A, Bennett C L. et al .
Performance measurement in pneumonia care: beyond report cards.
Mayo Clin Proc.
1998;
73 (1)
5-9
-
250
Sanyal S, Smith P R, Saha A C. et al .
Initial microbiologic studies did not affect outcome in adults hospitalized with community-acquired pneumonia.
Am J Respir Crit Care Med.
1999;
160 (1)
346-348
-
251
Wunderink R G, Waterer G W.
Appropriate microbiological testing in community-acquired pneumonia.
Chest.
2001;
119 (1)
5-7
-
252
Colice G L, Curtis A, Deslauriers J. et al .
Medical and surgical treatment of parapneumonic effusions: an evidence-based guideline.
Chest.
2000;
118 (4)
1158-1171
-
253
Heath C H, Grove D I, Looke D F.
Delay in appropriate therapy of Legionella pneumonia associated with increased mortality.
Eur J Clin Microbiol Infect Dis.
1996;
15 (4)
286-290
-
254
Gacouin A, Le Tulzo Y, Lavoue S. et al .
Severe pneumonia due to Legionella pneumophila: prognostic factors, impact of delayed appropriate antimicrobial therapy.
Intensive Care Med.
2002;
28 (6)
686-691
-
255
Gleason P P, Meehan T P, Fine J M. et al .
Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia.
Arch Intern Med.
1999;
159 (21)
2562-2572
-
256
Houck P M, MacLehose R F, Niederman M S. et al .
Empiric antibiotic therapy and mortality among medicare pneumonia inpatients in 10 western states: 1993, 1995, and 1997.
Chest.
2001;
119 (5)
1420-1426
-
257
Martinez J A, Horcajada J P, Almela M. et al .
Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia.
Clin Infect Dis.
2003;
36 (4)
389-395
-
258
Mufson M A, Stanek R J.
Bacteremic pneumococcal pneumonia in one American City: a 20-year longitudinal study, 1978 - 1997.
Am J Med.
1999;
107 (1A)
34S-43S
-
259
Stahl J E, Barza M, DesJardin J. et al .
Effect of macrolides as part of initial empiric therapy on length of stay in patients hospitalized with community-acquired pneumonia.
Arch Intern Med.
1999;
159 (21)
2576-2580
-
260
Baddour L M, Yu V L, Klugman K P. et al .
Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia.
Am J Respir Crit Care Med.
2004;
170 (4)
440-444
-
261
Finch R, Schurmann D, Collins O. et al .
Randomized controlled trial of sequential intravenous (i. v.) and oral moxifloxacin compared with sequential i. v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment.
Antimicrob Agents Chemother.
2002;
46 (6)
1746-1754
-
262
Correa J C, Badaro R, Bumroongkit C. et al .
Randomized, open-label, parallel-group, multicenter study of the efficacy and tolerability of IV gatifloxacin with the option for oral stepdown gatifloxacin versus IV ceftriaxone (with or without erythromycin or clarithromycin) with the option for oral stepdown clarithromycin for treatment of patients with mild to moderate community-acquired pneumonia requiring hospitalization.
Clin Ther.
2003;
25 (5)
1453-1468
-
263
Frank E, Liu J, Kinasewitz G. et al .
A multicenter, open-label, randomized comparison of levofloxacin and azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community-acquired pneumonia.
Clin Ther.
2002;
24 (8)
1292-1308
-
264
Vergis E N, Indorf A, File Jr T M. et al .
Azithromycin vs cefuroxime plus erythromycin for empirical treatment of community-acquired pneumonia in hospitalized patients: a prospective, randomized, multicenter trial.
Arch Intern Med.
2000;
160 (9)
1294-1300
-
265
Feldman R B, Rhew D C, Wong J Y. et al .
Azithromycin monotherapy for patients hospitalized with community-acquired pneumonia: a 31/2-year experience from a veterans affairs hospital.
Arch Intern Med.
2003;
163 (14)
1718-1726
-
266
Williams D, Perri M, Zervos M J.
Randomized comparative trial with ampicillin/sulbactam versus cefamandole in the therapy of community acquired pneumonia.
Eur J Clin Microbiol Infect Dis.
1994;
13 (4)
293-298
-
267
Norrby S R, Petermann W, Willcox P A. et al .
A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia.
Scand J Infect Dis.
1998;
30 (4)
397-404
-
268
Dansey R D, Jacka P J, Strachan S A. et al .
Comparison of cefotaxime with ceftriaxone given intramuscularly 12-hourly for community-acquired pneumonia.
Diagn Microbiol Infect Dis.
1992;
15 (1)
81-84
-
269
Brande P van den, Vondra V, Vogel F. et al .
Sequential therapy with cefuroxime followed by cefuroxime axetil in community-acquired pneumonia.
Chest.
1997;
112 (2)
406-415
-
270
Vetter N, Cambronero-Hernandez E, Rohlf J. et al .
A prospective, randomized, double-blind multicenter comparison of parenteral ertapenem and ceftriaxone for the treatment of hospitalized adults with community-acquired pneumonia.
Clin Ther.
2002;
24 (11)
1770-1785
-
271
Plouffe J, Schwartz D B, Kolokathis A. et al .
Clinical efficacy of intravenous followed by oral azithromycin monotherapy in hospitalized patients with community-acquired pneumonia. The Azithromycin Intravenous Clinical Trials Group.
Antimicrob Agents Chemother.
2000;
44 (7)
1796-1802
-
272
Sanchez F, Mensa J, Martinez J A. et al .
Is azithromycin the first-choice macrolide for treatment of community-acquired pneumonia?.
Clin Infect Dis.
2003;
36 (10)
1239-1245
-
273
Chien S M, Pichotta P, Siepman N. et al .
Treatment of community-acquired pneumonia. A multicenter, double-blind, randomized study comparing clarithromycin with erythromycin. Canada-Sweden Clarithromycin-Pneumonia Study Group.
Chest.
1993;
103 (3)
697-701
-
274
Salvarezza C R, Mingrone H, Fachinelli H. et al .
Comparison of roxithromycin with cefixime in the treatment of adults with community-acquired pneumonia.
J Antimicrob Chemother.
1998;
41 Suppl B
75-80
-
275
Ortqvist A, Valtonen M, Cars O. et al .
Oral empiric treatment of community-acquired pneumonia. A multicenter, double-blind, randomized study comparing sparfloxacin with roxithromycin. The Scandinavian Sparfloxacin Study Group.
Chest.
1996;
110 (6)
1499-1506
-
276
Oosterheert J J, Bonten M JM, Hak E. et al .
How good is the evidence for the recommended empirical antimicrobial treatment of patients hospitalized because of community-acquired pneumonia? A systematic review.
J Antimicrob Chemother.
2003;
52 (4)
555-563
-
277
Wasserfallen J B, Erard V, Cometta A. et al .
Cost-effectiveness of full-course oral levofloxacin in severe community-acquired pneumonia.
European Respiratory Journal.
2004;
24 (4)
644-648
-
278
Castro-Guardiola A, Viejo-Rodriguez A L, Soler-Simon S. et al .
Efficacy and safety of oral and early-switch therapy for community-acquired pneumonia: a randomized controlled trial.
Am J Med.
2001;
111 (5)
367-374
-
279
Ramirez J A, Srinath L, Ahkee S. et al .
Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia.
Arch Intern Med.
1995;
155 (12)
1273-1276
-
280
Paladino J A, Gudgel L D, Forrest A. et al .
Cost-effectiveness of IV-to-oral switch therapy: azithromycin vs cefuroxime with or without erythromycin for the treatment of community-acquired pneumonia.
Chest.
2002;
122 (4)
1271-1279
-
281
Rhew D C, Hackner D, Henderson L. et al .
The clinical benefit of in-hospital observation in ‘low-risk’ pneumonia patients after conversion from parenteral to oral antimicrobial therapy.
Chest.
1998;
113 (1)
142-146
-
282
Rhew D C, Tu G S, Ofman J. et al .
Early switch and early discharge strategies in patients with community-acquired pneumonia: a meta-analysis.
Arch Intern Med.
2001;
161 (5)
722-727
-
283
Siegel R E, Halpern N A, Almenoff P L. et al .
A prospective randomized study of inpatient iv. antibiotics for community-acquired pneumonia. The optimal duration of therapy.
Chest.
1996;
110 (4)
965-971
-
284
Bohte R, Wout J W van't, Lobatto S. et al .
Efficacy and safety of azithromycin versus benzylpenicillin or erythromycin in community-acquired pneumonia.
Eur J Clin Microbiol Infect Dis.
1995;
14 (3)
182-187
-
285
Chastre J, Wolff M, Fagon J Y. et al .
Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial.
JAMA.
2003;
290 (19)
2588-2598
-
286
Fine M J, Hanusa B H, Lave J R. et al .
Comparison of a disease-specific and a generic severity of illness measure for patients with community-acquired pneumonia.
J Gen Intern Med.
1995;
10 (7)
359-368
-
287
Samama M M, Cohen A T, Darmon J Y. et al .
A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group.
N Engl J Med.
1999;
341 (11)
793-800
-
288
Mundy L M, Leet T L, Darst K. et al .
Early mobilization of patients hospitalized with community-acquired pneumonia.
Chest.
2003;
124 (3)
883-889
-
289
Halm E A, Fine M J, Marrie T J. et al .
Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines.
JAMA.
1998;
279 (18)
1452-1457
-
290
Fine M J, Smith D N, Singer D E.
Hospitalization decision in patients with community-acquired pneumonia: a prospective cohort study.
Am J Med.
1990;
89 (6)
713-721
-
291
Fine M J, Singer D E, Hanusa B H. et al .
Validation of a pneumonia prognostic index using the MedisGroups Comparative Hospital Database.
Am J Med.
1993;
94 (2)
153-159
-
292
Halm E A, Fine M J, Kapoor W N. et al .
Instability on hospital discharge and the risk of adverse outcomes in patients with pneumonia.
Arch Intern Med.
2002;
162 (11)
1278-1284
-
293
Halm E A, Teirstein A S.
Clinical practice. Management of community-acquired pneumonia.
N Engl J Med.
2002;
347 (25)
2039-2045
-
294
Mittl Jr R L, Schwab R J, Duchin J S. et al .
Radiographic resolution of community-acquired pneumonia.
Am J Respir Crit Care Med.
1994;
149 (3 Pt 1)
630-635
-
295
Feinsilver S H, Fein A M, Niederman M S. et al .
Utility of fiberoptic bronchoscopy in non-resolving pneumonia.
Chest.
1990;
98
1322-1326
-
296
Waterer G W, Kessler L A, Wunderink R G.
Medium-Term Survival after Hospitalization with Community-Acquired Pneumonia.
Am J Respir Crit Care Med.
2004;
169 (8)
910-914
-
297
Mortensen E M, Kapoor W N, Chang C CH. et al .
Assessment of mortality after long-term follow-up of patients with community-acquired pneumonia.
Clin Infect Dis.
2003;
37
1617-1624
-
298
Mortensen E M, Coley C M, Singer D E. et al .
Causes of death for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team cohort study.
Arch Intern Med.
2002;
162 (9)
1059-1064
-
299
Baudouin S V.
The pulmonary physician in critical care. 3: critical care management of community acquired pneumonia.
Thorax.
2002;
57 (3)
267-271
-
300
Hook III E W, Horton C A, Schaberg D R.
Failure of intensive care unit support to influence mortality from pneumococcal bacteremia.
JAMA.
1983;
249 (8)
1055-1057
-
301
Kaplan V, Angus D C, Griffin M F. et al .
Hospitalized community-acquired pneumonia in the elderly: age- and sex-related patterns of care and outcome in the United States.
Am J Respir Crit Care Med.
2002;
165 (6)
766-772
-
302
Leroy O, Vandenbussche C, Coffinier C. et al .
Community-acquired aspiration pneumonia in intensive care units. Epidemiological and prognosis data.
Am J Respir Crit Care Med.
1997;
156
1922-1929
-
303
Cosentini R, Blasi F, Raccanelli R. et al .
Severe community-acquired pneumonia: a possible role for Chlamydia pneumoniae.
Respiration.
1996;
63
61-65
-
304
Feldman C, Ross S, Goolam Mahomed A. et al .
The aetiology of severe community-acquired pneumonia and its impact on initial, empiric, antimicrobial treatment.
Respir Med.
1995;
89
187-192
-
305
Marik P E.
The clinical features of severe community-acquired pneumonia presenting as septic shock. Norasept II Study Investigators.
J Crit Care.
2000;
15 (3)
85-90
-
306
Moine P, Vercken J B, Chevret S. et al .
Severe community-acquired pneumonia. Etiology, epidemiology, and prognosis factors.
Chest.
1994;
105
1487-1495
-
307
Ortiz-Ruiz G, Caballero-Lopez J, Friedland I R. et al .
A study evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults.
Clin Infect Dis.
2002;
34 (8)
1076-1083
-
308
Pachon J, Prados M D, Capote F. et al .
Severe community-acquired pneumonia. Etiology, prognosis, and treatment.
Am Rev Respir Dis.
1990;
142 (2)
369-373
-
309
Rello J, Ausina V, Ricart M. et al .
Impact of previous antimicrobial therapy on the etiology and outcome of ventilator-associated pneumonia.
Chest.
1993;
104 (4)
1230-1235
-
310
Bandyopadhyay T, Gerardi D A, Metersky M L.
A comparison of induced and expectorated sputum for the microbiological diagnosis of community acquired pneumonia.
Respiration.
2000;
67 (2)
173-176
-
311
Ewig S, Schlochtermeier M, Göke N. et al .
Applying sputum as a diagnostic tool in pneumonia: Limited yield, minimal impact on treatment decisions.
Chest.
2002;
121
1486-1492
-
312
Schaberg T, Dalhoff K, Ewig S. et al .
Empfehlungen zur Therapie der ambulant erworbenen Pneumonie. Deutsche Gesellschaft für Pneumologie.
Pneumologie.
1998;
52 (8)
450-462
-
313
Formica N, Yates M, Beers M. et al .
The impact of diagnosis by legionella urinary antigen test on the epidemiology and outcomes of Legionnaires' disease.
Epidemiol Infect.
2001;
127 (2)
275-280
-
314
Ruf B, Schurmann D, Horbach I. et al .
Prevalence and diagnosis of Legionella pneumonia: a 3-year prospective study with emphasis on application of urinary antigen detection.
J Infect Dis.
1990;
162 (6)
1341-1348
-
315
Jimenez P, Saldias F, Meneses M. et al .
Diagnostic fiberoptic bronchoscopy in patients with community-acquired pneumonia. Comparison between bronchoalveolar lavage and telescoping plugged catheter cultures.
Chest.
1993;
103 (4)
1023-1027
-
316
Kahn F W, Jones J H.
Analysis of bronchoalveolar lavage specimens from immunocompromized patients with a protocol applicable in the microbiology Iaboratory.
J CIin Microbiol.
1988;
26
1150-1155
-
317
Fink M P, Snydman D R, Niederman M S. et al .
Treatment of severe pneumonia in hospitalized patients: Results of a multicenter, randomized, double blind trial comparing intravenous ciprofloxacin with imipenem/cilastatin.
J Antimicrob Chemother.
1994;
38
547-557
-
318
Geddes A, Thaler M, Schonwald S. et al .
Levofloxacin in the empirical treatment of patients with suspected bacteraemia/sepsis: comparison with imipenem/cilastatin in an open, randomized trial.
J Antimicrob Chemother.
1999;
44 (6)
799-810
-
319
Niederman M S.
How do we optimize outcomes for patients with severe community-acquired pneumonia?.
Intensive Care Med.
2002;
28 (8)
1003-1005
-
320
Leophonte P, Veyssier P.
[Levofloxacin in the treatment of community-acquired pneumococcal pneumonia].
Presse Med.
1999;
28 (36)
1975-1979
-
321
Woodhead M, Ortqvist A.
Pulmonary infections: what to do when it's a bug that you do not know.
Eur Respir J.
2003;
21 (2)
201
-
322
Waterer G W, Somes G W, Wunderink R G.
Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia.
Arch Intern Med.
2001;
161 (15)
1837-1842
-
323
Bartlett J G.
Empirical therapy of community-acquired pneumonia: macrolides are not ideal choices.
Semin Respir Infect.
1997;
12 (4)
329-333
-
324
Safdar N, Handelsman J, Maki D G.
Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis.
Lancet Infect Dis.
2004;
4 (8)
519-527
-
325
Grimm H, Funke G.
Bedeutung der antibakteriellen Eigenaktivität von Sulbactam und Tazobactam für die Empfindlichkeitsprüfung von Inhibitor-geschützten Penicillinen.
Chemother J.
2004;
13 (6)
238-241
-
326
Paul M, Benuri-Silbiger I, Soares-Weiser K. et al .
b-lactam monotherapy versus b-lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials.
BMJ.
2004;
328-668
-
327
Chapman T M, Perry C M.
Cefepime: a review of its use in the management of hospitalized patients with pneumonia.
Am J Respir Med.
2003;
2 (1)
75-107
-
328
Fein A M, Feinsilver S H, Niederman M S. et al .
When pneumonia doesn't get better.
Clin Chest Med.
1987;
8
529-541
-
329
Ewig S, Schäfer H.
Lungenabszesse neu betrachtet. Eine klinisch handlungsanleitende Klassifikation.
Pneumologie.
2001;
55 (4)
195-201
-
330
Marrie T.
Normal resolution of community-acquired pneumonia.
Semin Respir Infect.
1992;
7
289-293
-
331
El Solh A A, Aquilina A T, Gunen H. et al .
Radiographic resolution of community-acquired bacterial pneumonia in the elderly.
J Am Geriatr Soc.
2004;
52 (2)
224-229
-
332
Metlay J P, Fine M J, Schulz R. et al .
Measuring symptomatic and functional recovery in patients with community-acquired pneumonia.
J Gen Intern Med.
1997;
12 (7)
423-430
-
333
The British Thoracic Society Research Committee and The Public Health Laboratory Service .
The aetiology, management and outcome of severe community-acquired pneumonia on the intensive care unit.
Respir Med.
1992;
86 (1)
7-13
-
334
Kirtland S H, Winterbauer R H.
Slowly resolving, chronic, and recurrent pneumonia.
Clin Chest Med.
1991;
12 (2)
303-318
-
335
Ortqvist A, Hedlund J, Grillner L. et al .
Aetiology, outcome and prognostic factors in patients with community acquired pneumonia requiring hospitalisation.
Eur Respir J.
1990;
3
1105-1113
-
336
Feinsilver S H, Fein A M, Teitcher J.
A practical approach to nonresolving pneumonia.
Semin Respir Infect.
1992;
7 (4)
289-293
-
337
Marrie T J, Durant H, Yates L.
Community acquired pneumonia requiring hospitalisation: 5-year prospective study.
Rev Infec Dis.
1989;
11
586-599
-
338
Finkelstein M S, Petkun W M, Freedman M L. et al .
Pneumococcal bacteremia in adults: age-dependent differences in presentation and in outcome.
J Am Geriatr Soc.
1983;
31 (1)
19-27
-
339
Menendez R, Perpina M, Torres A.
Evaluation of nonresolving and progressive pneumonia.
Semin Respir Infect.
2003;
18 (2)
103-111
-
340
Pereira Gomes J C, Pedreira Jr J W, Araujo E M. et al .
Impact of BAL in the management of pneumonia with treatment failure: positivity of BAL culture under antibiotic therapy.
Chest.
2000;
118 (6)
1739-1746
-
341
Muder R R.
Pneumonia in residents of long-term care facilities: epidemiology, etiology, management, and prevention.
Am J Med.
1998;
105 (4)
319-330
-
342
Franquet T.
Imaging of pneumonia: trends and algorithms.
Eur Respir J.
2001;
18 (1)
196-208
-
343
Tomiyama N, Muller N L, Johkoh T. et al .
Acute parenchymal lung disease in immunocompetent patients: diagnostic accuracy of high-resolution CT.
AJR Am J Roentgenol.
2000;
174 (6)
1745-1750
-
344
Marik P E.
Aspiration pneumonitis and aspiration pneumonia.
N Engl J Med.
2001;
344 (9)
665-671
-
345
Kikuchi R, Watabe N, Konno T. et al .
High incidence of silent aspiration in elderly patients with community-acquired pneumonia.
Am J Respir Crit Care Med.
1994;
150 (1)
251-253
-
346
Loeb M, McGeer A, McArthur M. et al .
Risk factors for pneumonia and other lower respiratory tract infections in elderly residents of long-term care facilities.
Arch Intern Med.
1999;
159 (17)
2058-2064
-
347
Nakagawa T, Sekizawa K, Arai H. et al .
High incidence of pneumonia in elderly patients with basal ganglia infarction.
Arch Intern Med.
1997;
157 (3)
321-324
-
348
El Solh A A, Pietrantoni C, Bhat A. et al .
Microbiology of severe aspiration pneumonia in institutionalized elderly.
Am J Respir Crit Care Med.
2003;
167 (12)
1650-1654
-
349
Matthay R A, Arroliga A C.
Resection of pulmonary metastases.
Am Rev Respir Dis.
1993;
148 (6 Pt 1)
1691-1696
-
350
Mwandumba H C, Beeching N J.
Pyogenic lung infections: factors for predicting clinical outcome of lung abscess and thoracic empyema.
Curr Opin Pulm Med.
2000;
6 (3)
234-239
-
351
Mansharamani N, Balachandran D, Delaney D. et al .
Lung abscess in adults: clinical comparison of immunocompromised to non-immunocompromised patients.
Respir Med.
2002;
96 (3)
178-185
-
352
Hammond J M, Potgieter P D, Hanslo D. et al .
The etiology and antimicrobial susceptibility patterns of microorganisms in acute community-acquired lung abscess.
Chest.
1995;
108 (4)
937-941
-
353
Mansharamani N G, Koziel H.
Chronic lung sepsis: lung abscess, bronchiectasis, and empyema.
Curr Opin Pulm Med.
2003;
9 (3)
181-185
-
354
Porta G, Rodriguez-Carballeira M, Gomez L. et al .
Thoracic infection caused by Streptococcus milleri.
Eur Respir J.
1998;
12 (2)
357-362
-
355
Wong C A, Donald F, Macfarlane J T.
Streptococcus milleri pulmonary disease: a review and clinical description of 25 patients.
Thorax.
1995;
50 (10)
1093-1096
-
356
Yang P C, Luh K T, Lee Y C. et al .
Lung abscesses: US examination and US-guided transthoracic aspiration.
Radiology.
1991;
180 (1)
171-175
-
357
Hammer D L, Aranda C P, Galati V. et al .
Massive intrabronchial aspiration of contents of pulmonary abscess after fiberoptic bronchoscopy.
Chest.
1978;
74 (3)
306-307
-
358
Gudiol F, Manresa F, Pallares R. et al .
Clindamycin vs penicillin for anaerobic lung infections. High rate of penicillin failures associated with penicillin-resistant Bacteroides melaninogenicus.
Arch Intern Med.
1990;
150 (12)
2525-2529
-
359
Levison M E, Mangura C T, Lorber B. et al .
Clindamycin compared with penicillin for the treatment of anaerobic lung abscess.
Ann Intern Med.
1983;
98 (4)
466-471
-
360
Allewelt M, Schuler P, Bolcskei P L. et al .
Ampicillin + sulbactam vs clindamycin +/- cephalosporin for the treatment of aspiration pneumonia and primary lung abscess.
Clin Microbiol Infect.
2004;
10 (2)
163-170
-
361
Fernandez-Sabe N, Carratala J, Dorca J. et al .
Efficacy and safety of sequential amoxicillin-clavulanate in the treatment of anaerobic lung infections.
Eur J Clin Microbiol Infect Dis.
2003;
22 (3)
185-187
-
362
Klein J S, Schultz S, Heffner J E.
Interventional radiology of the chest: image-guided percutaneous drainage of pleural effusions, lung abscess, and pneumothorax.
AJR Am J Roentgenol.
1995;
164 (3)
581-588
-
363
Sonnenberg E van, D'Agostino H B, Casola G. et al .
Lung abscess: CT-guided drainage.
Radiology.
1991;
178 (2)
347-351
-
364
Fraser D W, Tsai T R, Orenstein W. et al .
Legionnaires' disease: description of an epidemic of pneumonia.
N Engl J Med.
1977;
297 (22)
1189-1197
-
365
Ewig S, Tuschy P, Fätkenheuer G.
Diagnostik und Therapie der Legionellen-Pneumonie.
Pneumologie.
2003;
56 (11)
695-703
-
366
Yu V L, Greenberg R N, Zadeikis N. et al .
Levofloxacin Efficacy in the Treatment of Community-Acquired Legionellosis.
Chest.
2004;
125 (6)
2135-2139
-
367
Dunbar L M, Khashab M M, Kahn J B. et al .
Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens.
Curr Med Res Opin.
2004;
20 (4)
555-563
-
368
Schonwald S, Kuzman I, Oreskovic K. et al .
Azithromycin: single 1.5 g dose in the treatment of patients with atypical pneumonia syndrome - a randomized study.
Infection.
1999;
27 (3)
198-202
-
369
Gorak E J, Yamada S M, Brown J D.
Community-acquired methicillin-resistant Staphylococcus aureus in hospitalized adults and children without known risk factors.
Clin Infect Dis.
1999;
29 (4)
797-800
-
370
Nimmo G R, Playford E G.
Community-acquired MRSA bacteraemia: four additional cases including one associated with severe pneumonia.
Med J Aust.
2003;
178 (5)
245
-
371
Dufour P, Gillet Y, Bes M. et al .
Community-acquired methicillin-resistant Staphylococcus aureus infections in France: emergence of a single clone that produces Panton-Valentine leukocidin.
Clin Infect Dis.
2002;
35 (7)
819-824
-
372
Witte W, Cuny C, Strommenger B. et al .
Emergence of a new community acquired MRSA strain in Germany.
Euro Surveill.
2004;
9 (1)
1-2
-
373
Rubinstein E, Cammarata S, Oliphant T. et al .
Linezolid (PNU-100 766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study.
Clin Infect Dis.
2001;
32 (3)
402-412
-
374
Stevens D L, Herr D, Lampiris H. et al .
Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections.
Clin Infect Dis.
2002;
34 (11)
1481-1490
-
375
Torres A, Bauer T T, Leon C. et al .
Treatment of severe nosocomial pneumonia requiring mechanical ventilation: A prospective randomized comparison of intravenous ciprofloxacin with imipenem/cilastatin.
Thorax.
2000;
55 (12)
1033-1039
-
376
Hilf M, Yu V L, Sharp J T. et al .
Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients.
Am J Med.
1989;
87
540-546
-
377
Marrie T J.
Q fever pneumonia.
Current Opinion in Infectious Diseases.
2004;
17 (2)
137-142
-
378
British Thoracic Society .
BTS Guidelines for the Management of Community Acquired Pneumonia in Adults.
Thorax.
2001;
56 (90 004)
1iv-64
-
379
Raoult D, Torres H, Drancourt M.
Shell-vial assay: evaluation of a new technique for determining antibiotic susceptibility, tested in 13 isolates of Coxiella burnetii.
Antimicrob Agents Chemother.
1991;
35 (10)
2070-2077
-
380
Gikas A, Kofteridis D P, Manios A. et al .
Newer Macrolides as Empiric Treatment for Acute Q Fever Infection.
Antimicrob Agents Chemother.
2001;
45 (12)
3644-3646
-
381
Musso D, Drancourt M, Osscini S. et al .
Sequence of quinolone resistance-determining region of gyrA gene for clinical isolates and for an in-vitro-selected quinolone-resistant strain of Coxiella burnetii.
Antimicrob Agents Chemother.
1996;
40 (4)
870-873
-
382
Beyer W E, Palache A M, Jong J C de. et al .
Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta-analysis.
Vaccine.
2002;
20 (9 - 10)
1340-1353
-
383
Govaert T M, Sprenger M J, Dinant G J. et al .
Immune response to influenza vaccination of elderly people. A randomized double-blind placebo-controlled trial.
Vaccine.
1994;
12 (13)
1185-1189
-
384
Roos-Van Eijndhoven D G, Cools H J, Westendorp R G. et al .
Randomized controlled trial of seroresponses to double dose and booster influenza vaccination in frail elderly subjects.
J Med Virol.
2001;
63 (4)
293-298
-
385
O'Donnell D E, Fluge T, Gerken F. et al .
Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD.
European Respiratory Journal.
2004;
23 (6)
832-840
-
386
Gross P A, Hermogenes A W, Sacks H S. et al .
The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature.
Ann Intern Med.
1995;
123 (7)
518-527
-
387
Nichol K L, Margolis K L, Wuorenma J. et al .
The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community.
N Engl J Med.
1994;
331 (12)
778-784
-
388
Nichol K L, Wuorenma J, Sternberg T von.
Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens.
Arch Intern Med.
1998;
158 (16)
1769-1776
-
389
Beyer W E, Bruijn I A de, Palache A M. et al .
Protection against influenza after annually repeated vaccination: a meta-analysis of serologic and field studies.
Arch Intern Med.
1999;
159 (2)
182-188
-
390
STIKO .
Empfehlungen der ständigen Impfkommission (STIKO) am Robert-Koch-Institut/Stand Juli 2002.
Epidemiol Bull.
2002;
28
227-242
-
391
Hedlund J U, Kalin M E, Ortqvist A B. et al .
Antibody response to pneumococcal vaccine in middle-aged and elderly patients recently treated for pneumonia.
Arch Intern Med.
1994;
154 (17)
1961-1965
-
392
Carson P J, Nichol K L, O'Brien J. et al .
Immune function and vaccine responses in healthy advanced elderly patients.
Arch Intern Med.
2000;
160 (13)
2017-2024
-
393
Konradsen H B.
Quantity and avidity of pneumococcal antibodies before and up to five years after pneumococcal vaccination of elderly persons.
Clin Infect Dis.
1995;
21 (3)
616-620
-
394
Jackson L A, Benson P, Sneller V P. et al .
Safety of revaccination with pneumococcal polysaccharide vaccine.
JAMA.
1999;
281 (3)
243-248
-
395
Fine M J, Smith M A, Carson C A. et al .
Efficacy of pneumococcal vaccination in adults. A meta-analysis of randomized controlled trials.
Arch Intern Med.
1994;
154 (23)
2666-2677
-
396
Watson L, Wilson B J, Waugh N.
Pneumococcal polysaccharide vaccine: a systematic review of clinical effectiveness in adults.
Vaccine.
2002;
20 (17 - 18)
2166-2173
-
397
Moore R A, Wiffen P J, Lipsky B A.
Are the pneumococcal polysaccharide vaccines effective? Meta-analysis of the prospective trials.
BMC Fam Pract.
2000;
1 (1)
1
-
398
Cornu C, Yzebe D, Leophonte P. et al .
Efficacy of pneumococcal polysaccharide vaccine in immunocompetent adults: a meta-analysis of randomized trials.
Vaccine.
2001;
19 (32)
4780-4790
-
399
Talbot T R, Poehling K A, Hartert T V. et al .
Reduction in high rates of antibiotic-nonsusceptible invasive pneumococcal disease in Tennessee after introduction of the pneumococcal conjugate vaccine.
Clin Infect Dis.
2004;
39
641-648
-
400
Christenson B, Lundbergh P, Hedlund J. et al .
Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in adults aged 65 years or older: a prospective study.
Lancet.
2001;
357 (9261)
1008-1011
-
401
Trosini-Desert V, Germaud P, Dautzenberg B.
Tobacco smoke and risk of bacterial infection.
Rev Mal Respir.
2004;
21 (3 Pt 1)
539-547
-
402 Dietrich E S, Brockmann S, Frank U WE. et al .The economic impact of unnecessary hospital admissions of patients with community acquired pneumonia. 15th Annual Meeting of the ISTAHC 1999
-
403
Oostenbrink J, Buijs-Van der Woude T, Agthoven M van. et al .
Unit costs of inpatient hospital days.
Pharmacoeconomics.
2003;
21 (4)
263-271
-
404
Ramirez J A, Vargas S, Ritter G W. et al .
Early switch from intravenous to oral antibiotics and early hospital discharge: a prospective observational study of 200 consecutive patients with community-acquired pneumonia.
Arch Intern Med.
1999;
159 (20)
2449-2454
-
405
Suwangool P, Moola-Or P, Waiwatana A. et al .
Effect of a selective restriction policy on antibiotic expenditure and use: an institutional model.
J Med Assoc Thai.
1991;
74 (7)
272-275
-
406
Dietrich E S, Schmid M, Bucher A. et al .
Kostenreduktion in der Antibiotika-Therapie.
Krankenhauspharmazie.
1998;
19 (6)
287-292
-
407
O'Hanley P, Rodondi L, Coleman R.
Efficacy and cost-effectiveness of antibiotic monitoring at a Veterans Administration hospital.
Chemotherapy.
1991;
37 (Suppl. 3)
22-25
-
408
Coley K C.
Changing physician prescribing behavior: The Community-Acquired Pneumonia Intervention Trial.
Am J Health Syst Pharm Ref Type Journal (Full).
2000;
57 (15)
1506-1510
-
409
Böhmer W, Loos U, Heissenberg A. et al .
Leitliniengesteuertes infektioloisches Qualitätsmanagement auf einer internistischen Allgemeinstation bei Patienten mit ambulant erworbener Pneumonie.
Chemother J.
2002;
11
83-86
-
410
Lemmen S W, Hafner H, Kotterik S. et al .
Influence of an infectious disease service on antibiotic prescription behavior and selection of multiresistant pathogens.
Infection.
2000;
28 (6)
384-387
-
411
Dietrich E S, Jopp R, Schreier U. et al .
Kosten einer leitliniengerechten Arzneimitteltherapie in Deutschland.
Gesundh ökon Qual manag.
2005;
10
35-43
-
412
Omidvari K, Boisblanc B P de, Karam G. et al .
Early transition to oral antibiotic therapy for community-acquired pneumonia: duration of therapy, clinical outcomes, and cost analysis.
Respir Med.
1998;
92 (8)
1032-1039
-
413
Ambrose P G, Quintiliani R, Nightingale C H. et al .
Continuous vs. intermittent infusion of cefuroxime for the treatment of community-acquired pneumonia.
Infect Dis Clin Pract.
1998;
7
463-470
-
414
Schädlich P K, Huppertz E, Brecht J G.
Levofloxacin versus relevant alternatives in inpatient treatment of community-acquired pneumonia: results of a german economic evaluation. (Abstract T105).
Antiinfect Drugs Chemother.
1998;
16 (Suppl. 1)
62
-
415
Richerson M A, Ambrose P G, Quintiliani R. et al .
Pharmacoeconomic evaluation of alternative antibiotic regimens in hospitalized patients with community-acquired pneumonia.
Infect Dis Clin Pract.
1998;
7
227-233
-
416
Jäcker A.
Was sparen Generika wirklich? - Eine Analyse aus volkswirtschaftlicher Perspektive.
Ges Pol.
2004;
2004 (1)
1-4
-
417 Standing Medical Advisory Committee .The Path of Least Resistance. London, UK: Department of Health 1998
-
418
Kaptchuk T J.
The placebo effect in alternative medicine: can the performance of a healing rutual have clinical significance?.
Ann Intern Med.
2002;
136
817-825
-
419
Wandstrat T L, Kaplan B.
Pharmacoeconomic impact of factors affecting compliance of antibiotic regimens in the treatment of acute otitis media.
Pediatr Infect Dis J.
1997;
16 (Suppl. 2)
S27-S29
-
420
Einarsson S, Kristjansson M, Kristinsson K G. et al .
Pneumonia caused by penicillin-non-susceptible and penicillin-susceptible pneumococci in adults: a case-control study.
Scand J Infect Dis.
1998;
30 (3)
253-256
-
421
Klerk G J de, Steijn J H van, Lobatto S. et al .
A randomised, multicentre study of ceftriaxone versus standard therapy in the treatment of lower respiratory tract infections.
Int J Antimicrob Agents.
1999;
12 (2)
121-127
-
422
Dietrich E S, Joseph U, Vogel F. et al .
Cost-effectiveness of ceftriaxone 1 g vs second-generation cephalosporins in the treatment of pneumonia in general medical wards in Germany.
Infection.
1999;
27 (2)
148-154
-
423
Siegel R E, Alicea M, Lee A. et al .
Comparison of 7 versus 10 days of antibiotic therapy for hospitalized patients with uncomplicated community-acquired pneumonia: A prospective, randomized, double-blind study.
Am J Ther.
1999;
6 (4)
217-222
-
424
Groth J J.
A pahrmacoeconomic study: clarithromycin in bronchitis and pneumonia.
Klinikarzt.
1998;
4 (27)
22-24
-
425
Huber S L, Wood J S, Weston J S. et al .
Antibiotic therapy in community-acquired pneumonia and the role of the hospital pharmacist.
Am J Man Care.
1999;
5 (9)
S555-S569
-
426
Hueston W J, Mainous A G, Brauer N. et al .
Evaluation and treatment of respiratory infections: does managed care make a difference?.
J Fam Pract.
1997;
44 (6)
572-577
-
427
Stelianides S, Golmard J L, Carbon C. et al .
Influence of socioeconomic status on features and outcome of community-acquired pneumonia.
Eur J Clin Microbiol Infect Dis.
1999;
18 (10)
704-708
Prof. Dr. med. G. Höffken
Universitätsklinikum Carl Gustav Carus Dresden · Medizinische Klinik I
Fetscherstr. 74
01307 Dresden ·
Email: gert.hoeffken@uniklinikum-dresden.de ·
Email: prof.hoeffken@fachkrankenhaus-coswig.de
